Pharming Technologies B.V. clinical trials

A subsidiary of Pharming Group N.V.

The registry lists 22 studies whose lead sponsor is Pharming Technologies B.V.. 3 are recruiting or about to start. Per ClinicalTrials.gov, last updated Oct 19, 2026.

Studies

Recruiting first, then most recently updated. Showing 22 of 22. All Pharming Group N.V. studies →

• Open Label Extension to Assess Long Term Safety and Efficacy of KL1333 in Patients With Primary Mitochondrial DiseaseRecruitingNCT07514338Phase 2

  Sponsor listed in the registry: Pharming Technologies B.V.

• Efficacy of KL1333 in Adult Patients With Primary Mitochondrial DiseaseRecruitingNCT05650229Phase 2

  Sponsor listed in the registry: Pharming Technologies B.V.

• An Open-Label Study to Assess the Safety & Efficacy of Leniolisib in Japanese Patients With APDSRecruitingNCT06249997Phase 3

  Sponsor listed in the registry: Pharming Technologies B.V.

• Leniolisib for Immune Dysregulation in PIDsCompletedNCT06549114Phase 2

  Sponsor listed in the registry: Pharming Technologies B.V.

• Leniolisib for Immune Dysregulation in CVIDCompletedNCT06897358Phase 2

  Sponsor listed in the registry: Pharming Technologies B.V.

• Long-term Safety and Efficacy of Leniolisib in PIDs With Immune DysregulationActive, not recruitingNCT06990529Phase 2

  Sponsor listed in the registry: Pharming Technologies B.V.

• Pediatric Patients Aged 1 to 6 Years With APDSActive, not recruitingNCT05693129Phase 3

  Sponsor listed in the registry: Pharming Technologies B.V.

• Pediatric Patients Aged 4 to 11 Years With APDSActive, not recruitingNCT05438407Phase 3

  Sponsor listed in the registry: Pharming Technologies B.V.

• Extension to the Study of Efficacy of CDZ173 in Patients With APDS/PASLITerminatedNCT02859727Phase 2/3

  Sponsor listed in the registry: Pharming Technologies B.V.

• C1 Inhibitor Registry in the Treatment of Hereditary Angioedema (HAE) AttacksCompletedNCT01397864

  Sponsor listed in the registry: Pharming Technologies B.V.

• Patient Registry to Evaluate the Real-world Safety of Ruconest®CompletedNCT03697187

  Sponsor listed in the registry: Pharming Technologies B.V.

• Prevention of Acute Kidney Injury in Patients With NSTEMITerminatedNCT04912141Phase 2

  Sponsor listed in the registry: Pharming Technologies B.V.

• Safety of Ruconest in 2-13 Year Old Hereditary Angioedema (HAE) PatientsCompletedNCT01359969Phase 2

  Sponsor listed in the registry: Pharming Technologies B.V.

• Prevention of Severe SARS-CoV-2 Infection in Hospitalized Patients With COVID-19CompletedNCT04530136Phase 2

  Sponsor listed in the registry: Pharming Technologies B.V.

• A Study of the Safety and Immunogenicity of Repeated rhC1INH AdministrationCompletedNCT00851409Phase 2

  Sponsor listed in the registry: Pharming Technologies B.V.

• A Phase 2 HAE Prophylaxis Study With Recombinant Human C1 InhibitorCompletedNCT02247739Phase 2

  Sponsor listed in the registry: Pharming Technologies B.V.

• Efficacy, Safety and Immunogenicity Study of Recombinant Human C1 Inhibitor for the Treatment of Acute HAE AttacksCompletedNCT01188564Phase 3

  Sponsor listed in the registry: Pharming Technologies B.V.

• Recombinant Human C1 Inhibitor for the Treatment of Acute Attacks in Patients With Hereditary AngioedemaCompletedNCT00261053Phase 2

  Sponsor listed in the registry: Pharming Technologies B.V.

• Recombinant Human C1 Inhibitor for the Treatment of Acute Attacks in Patients With Hereditary AngioedemaCompletedNCT00262288Phase 2/3

  Sponsor listed in the registry: Pharming Technologies B.V.

• Recombinant Human C1 Inhibitor for the Treatment of Acute Attacks in Patients With Hereditary AngioedemaCompletedNCT00225147Phase 2/3

  Sponsor listed in the registry: Pharming Technologies B.V.

• Recombinant Human C1 Inhibitor for the Treatment of Acute Attacks in Patients With Hereditary AngioedemaCompletedNCT00262301Phase 3

  Sponsor listed in the registry: Pharming Technologies B.V.

• Recombinant Human C1 Inhibitor for the Treatment of Early Antibody-Mediated Rejection in Renal TransplantationWithdrawnNCT01035593Phase 2

  Sponsor listed in the registry: Pharming Technologies B.V.